OncRef

Clinical Trial: NCT04521686

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:Eli Lilly and Company
Information Provided By:Eli Lilly and Company
Last Update Posted:2026-07-22

Study Overview

Brief Summary

This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine 140 (R140) or arginine 172 (R172) mutant cholangiocarcinoma.

Official Title

A Phase 1 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Conditions

Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor

Intervention / Treatment

  • Drug: LY3410738
  • Drug: Gemcitabine
  • Drug: Cisplatin
  • Drug: Durvalumab

Other Study ID Numbers

  • 18077
  • 2020-002863-77
  • I9Y-OX-JDHC
  • LOXO-IDH-20002

Start Date (Actual)

2020-10-01

Primary Completion Date (Actual)

2023-07-17

Study Completion Date (Estimated)

2027-05

Enrollment (Estimated)

200

Study Type

Interventional

Phase

Phase 1